Photonic devices, systems, and methods for detecting an analyte in a biological solution (e. G., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. ...

Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (pkd) in a patient, diagnosing pkd in a patient, staging pkd in a patient, and monitoring pkd in a patient. These methods include determining a single or multiple levels of one or more markers selected from the group of proliferating cell nuclear antigen (pcna), cyclin d1, ...

Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding ar mechanism (graft biopsy), as well as monitoring by minimal invasive ...

The present invention relates to new aptamer molecules for use in the treatment and/or diagnosis of autoimmune diseases associated with autoantibodies against g-protein coupled receptors, a pharmaceutical composition comprising such aptamer molecules, an apheresis column comprising such aptamer molecules and a method for the determination of nucleotide sequences for use as sequences of aptamer molecules.

The present disclosure provides antibodies that bind complement c1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

The present disclosure provides antibodies that bind complement c1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement c1s antibodies inhibit proteolytic activity of c1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.

Antibodies that bind the apple 2 domain of human coagulation factor xi and inhibit activation of fxi by coagulation factor xiia are described.

Provided are bispecific antibodies comprised of a single-chain unit having specificity to an immune cell and a monovalent unit having specificity to a tumor cell or a microorganism. The single-chain unit includes a single-chain variable fragment (scfv) fused to an fc fragment and the monovalent unit includes a light chain and heavy chain pair. Also provided are methods of preparing ...

The present disclosure relates to a method for inhibiting cancer tumor growth in a patient by administering to the patient a therapeutic monoclonal antibody specific for a tumor associated antigen in combination with at least one immunostimulatory compound, and at least one immune homeostatic checkpoint inhibitor. Also disclosed are uses, compositions and kits thereof.

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, ...

The present invention relates to combination therapies for treating a solid tumour in a subject. The combination therapies comprise (a) an antibody, or antigen-binding portion thereof, that specifically binds to cd40, and (b) a further immunotherapeutic agent with efficacy in the treatment of cancer, which agent is not an anti-cd40 antibody or antigen-binding fragment thereof. The invention also relates to ...

There is disclosed compositions and methods relating to or derived from anti-cd137 antibodies. More specifically, there is disclosed fully human antibodies that bind cd137, cd137-antibody binding fragments and derivatives of such antibodies, and cd137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, ...

The present invention relates to novel antibodies against the fgf receptor 4 (fgfr4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with fgfr expression, over expression or hyperactivity.

Anti-ctla-4 antibodies are disclosed. Also disclosed are compositions comprising such antibodies, and uses and methods using the same.

Disclosed herein are recognition molecules that bind with a first binding domain to the fc epsilon receptor (fcεer) and with a second binding domain to the fc gamma receptor iib (fcyriib), as well as uses for such recognition molecules.

The present inventors discovered that antigen uptake into cells is facilitated by an antibody having human fcrn-binding activity at the plasma ph and a lower antigen-binding activity at the early endosomal ph than at the plasma ph; such antibodies can increase the number of antigens to which a single antibody molecule can bind; the reduction of antigen in plasma can ...

Disclosed are methods and compositions of anti-b cell antibodies, preferably anti-cd22 antibodies, for diagnosis, prognosis and therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-b cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention. In other embodiments, optimal dosages of therapeutic antibody may ...

The invention relates to anti-tnfa antibodies which are engineered to exhibit a ph-sensitive antigen binding. The invention is preferably directed to anti-tnfa antibody adalimumab (humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to ...

The present invention provides compositions and methods which involve specifically antagonizing gdf8 and activin a. In certain embodiments, compositions are provided which comprise a gdf8-specific binding protein and an activin a-specific binding protein. For example, the invention includes compositions comprising an anti-gdf8 antibody and an anti-activin a antibody. In other embodiments, antigen-binding molecules are provided which comprise a gdf8...

The invention relates to the diagnosis and treatment of diseases, including cancer and inflammatory disorders. The invention provides, and involves the use of, antibodies that bind collagen.